Alpine Immune Sciences share updated clinical data for povetacicept in IgAN

The company states: “Alpine Immune Sciences shared updated clinical data for povetacicept in IgA nephropathy which will be presented as a late breaking poster at the World Congress of Nephrology April 13-16, 2024 in Buenos Aires, Argentina. Key Highlights Include: As of March 01, 2024, 41 patients with IgAN had received povetacicept 80 or 240 mg subcutaneously every 4 weeks. Treatment with povetacicept 80 mg SC Q4W has been associated with a clinically meaningful improvement in proteinuria, with a 64.1% reduction from baseline in urine protein to creatinine ratio (UPCR; n=6) at 36 weeks, associated with stable renal function as assessed by estimated glomerular filtration rate (eGFR). At this same time, 4/6 (67%) had achieved remission, as defined as UPCR less than 0.5 g/g, greater than or equal to50% reduction in UPCR from baseline, and stable renal function (less than or equal to 25% reduction in eGFR from baseline). Resolution of hematuria, as defined as negative or trace/small hematuria in patients with non-negative/trace hematuria at baseline, was achieved in all (100%) patients with data available at 36 or more weeks (N=4). Treatment with povetacicept 240 mg SC Q4W has been associated with similar improvements in proteinuria, stable renal function, and remission, based on initial data through 12 (13 patients) and 24 (2 patients) weeks. Treatment with both doses was associated with significant reductions in the key disease-related biomarker Gd-IgA1, with the 80 mg dose achieving a 68.9% reduction at 40 weeks, and the 240 mg dose achieving a 78.6% reduction at 20 weeks. Both doses achieved reductions in IgA/C3 and Gd-IgA1/C3 ratios, which are additional severity and prognostic biomarkers in IgAN. Both doses have been well tolerated in IgAN, with no instances of IgG less than 3 g/L and no severe infections.”